203718-08-5

Basic information

• Product Name: methyl 2,3-dibromo-3-(4-fluorophenyl)propanoate
• Synonyms: methyl 2,3-dibromo-3-(4-fluorophenyl)propanoate
• CAS NO: 203718-08-5
• Molecular Weight: 339.987
• Mol File: 203718-08-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl 2,3-dibromo-3-(4-fluorophenyl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2,3-dibromo-3-(4-fluorophenyl)propanoate(203718-08-5)
• EPA Substance Registry System: methyl 2,3-dibromo-3-(4-fluorophenyl)propanoate(203718-08-5)

Safety Data

• Hazardous Substances Data: 203718-08-5(Hazardous Substances Data)

Upstream product

• 100891-10-9 methyl p-fluorocinnamate 
• 459-32-5 4-fluorocinnamic acid 
• 459-32-5 (E)-4-fluorocinnamic acid 
• 96426-60-7 methyl (2E)-3-(4-fluorophenyl)-2-propenoate 

Downstream Products

• 706-06-9 3-(4-flurophenyl)prop-2-ynoic acid 
• 203718-24-5 ethyl 2-acetamido-2-(ethoxycarbonyl)-3-[5-(4-fluorophenyl)-2-(methoxymethyl)-3-oxoisoxazolin-4-yl]propanoate 
• 203718-20-1 4-(bromomethyl)-5-(4-fluorophenyl)-2-(methoxymethyl)isoxazolin-3-one 
• 195715-70-9 5-(4-fluorophenyl)-3-hydroxyisoxazole 

Relevant articles and documents

Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives

A series of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives were designed, synthesized and evaluated for their in vitro antibacterial activity. The results showed that the majority of the target compounds displayed potent activity against erythromycin-susceptible S. pyogenes, erythromycin-resistant S. pneumoniae A22072 expressing the mef gene and S. pneumoniae AB11 expressing the mef and erm genes. Besides, most of the target compounds exhibited moderate activity against erythromycin-susceptible S. aureus ATCC25923 and B. subtilis ATCC9372. In particular, compounds 11a, 11b, 11c, 11e, 11f and 11h were found to exert favorable antibacterial activity against erythromycin-susceptible S. pyogenes with the MIC values of 0.015–0.125 μg/mL. Furthermore, compounds 10e, 11a, 11b and 11c showed superior activity against erythromycin-resistant S. pneumoniae A22072 with the MIC values of 0.25–0.5 μg/mL. Additionally, compound 11c was the most effective against all the erythromycin-resistant S. pneumoniae strains (A22072, B1 and AB11), exhibiting 8-, 8- and 32-fold more potent activity than clarithromycin, respectively.